Eli Lilly Reports Positive Phase 3 Data From Lebrikizumab Trial

Eli Lilly has announced positive results from a phase 3 trial of its investigational drug, lebrikizumab, in patients with moderate-to-severe eczema.

The 211-participant study met its primary endpoints of clear or almost-clear skin plus a minimum of 75 percent change compared to baseline. Patients given lebrikizumab plus standard-of-care topical corticosteroids achieved an improvement of at least 75 percent in their disease severity, the company said.

Lebrikizumab, a monoclonal antibody that binds to the interleukin 13 protein, was granted Fast-Track designation by the FDA in December 2019 for the treatment of atopic dermatitis. The drug is a potential rival for Regeneron’s Dupixent (dupilumab).